Exploring the Potential of Calebin-A in Targeting Obesity-Related Genes and Pathways

Scritto il 13/06/2026
da Ali Mahmoudi

J Cell Mol Med. 2026 Jun;30(11):e71244. doi: 10.1111/jcmm.71244.

ABSTRACT

Obesity is a global health crisis affecting millions, associated with metabolic disorders such as type 2 diabetes and cardiovascular disease. Calebin-A, a bioactive compound derived from Curcuma species, has shown promise in managing obesity and its complications. This study utilized bioinformatics tools to explore the molecular mechanisms of Calebin-A in obesity. Transcriptomic data from obese and normal omental adipose tissue (GSE286454) were analysed, identifying 317 differentially expressed genes (DEGs). Functional enrichment analysis indicated a notable engagement of lysosomal activity, immune response, cell migration, axon guidance and apoptosis pathways. A STRING-based protein-protein interaction network revealed nine hub genes through a composite centrality score. Among these, CTSB, CTSZ, CTSA, GRN and TUBB exhibited upregulation and were prioritized for subsequent analysis. External validation (GSE59034; 16 obese vs. 16 controls) corroborated the consistent upregulation of CTSB, CTSZ, GRN and CTSA. Target prediction analysis identified 443 potential targets for Calebin-A, with pathway-level overlap suggesting a convergence on immune, lysosomal and cytoskeletal processes. Molecular docking studies indicated favourable binding affinities (-5.2 to -7.1 kcal/mol), with CTSZ demonstrating the most robust interaction. A 100 ns molecular dynamics simulation validated structural stability and indicated favourable binding free energy (MM-PBSA ΔG ≈ -110 kJ/mol). Results suggest that Calebin-A targets genes and proteins involved in energy balance and inflammation, offering insights into its anti-obesity potential. These findings provide a foundation for experimental validation and therapeutic development.

PMID:42286733 | DOI:10.1111/jcmm.71244